COMPANY
TREKKA Therapeutics
Funding and NIH signals
- NIH award NIH awarded $283K (STTR Phase I 5R41DE034604-02, continuation, notice Aug 14, 2026). NIH RePORTER 5R41DE034604-02 (Aug 14, 2026)
Evidence (1 event)
- Aug 14, 2026 · NIH RePORTER 5R41DE034604-02
Organization: TREKKA THERAPEUTICS, LLC; City/State: SAINT PAUL, MN; Project number: 5R41DE034604-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 283223; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Nanodroplet Infused Analgesic-Wafer for Transmucosal Opioid-free Treatment of Subacute Oral Pain; Organization type: Domestic For-Profits
- Aug 14, 2026 · NIH RePORTER 5R41DE034604-02
Timeline
- Grant Government grant — STTR: $283,223 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
- Grant Government grant — STTR: $413,298 (annual award, as published), announced Sep 4, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Funding
- Government grant — STTR: $283,223 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
- Government grant — STTR: $413,298 (annual award, as published), announced Sep 4, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
NIH awards 2
- NIH award 3R41CA278184-01A1S1 FY2023: $147,823 awarded for that fiscal year; activity R41 (STTR); PI WANG, CHUN; recipient as written: TREKKA THERAPEUTICS, LLC, SAINT PAUL, MN. A Novel Melanoma Vaccine Based on a Sha source ↗
- NIH award 1R41CA278184-01A1 FY2023: $399,979 awarded for that fiscal year; activity R41 (STTR); PI WANG, CHUN; recipient as written: TREKKA THERAPEUTICS, LLC, SAINT PAUL, MN. A Novel Melanoma Vaccine Based on a Share source ↗